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gets speciﬁc pathways is changing the therapeutic approach to
hepatocellular carcinoma. For several aberrantly activated path-
ways in hepatocarcinoma, surrogate markers of activation can
be assessed by immunohistochemistry, although associations
with in vivo response to targeted therapies are still lacking.
Methods: A patient, who presented with hepatic and extra-hepa-
tic hepatocarcinoma recurrence 11 years after liver transplanta-
tion, was assessed for b-catenin, pERK, and pS6 in primary and
secondary tumor specimens, in order to deﬁne a possible activa-
tion of the Wnt, Ras/MAPK and Akt/mTOR pathways and design a
personalized targeted therapy in absence of alternative treatment
options. Moreover, mutation analysis of the b-catenin gene
(CTNNB1) and DNA microsatellite analyses were performed.
Results: The identiﬁcation of the same mutation in the b-catenin
gene, as well as the same microsatellite pattern in tumor tissues
taken 11 years apart, proved that the observed hepatocarcinoma
was a true recurrence. Nuclear b-catenin and pS6 in tumor cells
were positive, whereas pERK was positive only in the peritumoral
endothelium. This pattern of immunohistochemistry, after failure
of sorafenib alone, lead to the choice to add the mTOR inhibitor,
everolimus, to sorafenib. Three months later a 50% tumor reduc-
tion was observed, and after 6 months a further reduction of
tumor vital components was conﬁrmed, while a grade II gastroin-
testinal bleeding episode occurred.Journal of Hepatology 20
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vascular endothelial growth factor receptor.hepatocarcinoma is possible through analysis of tumoral molecu-
lar pathways. Partial success of the selected combination of
sorafenib and everolimus supports the pivotal role of mTOR sig-
nalling and highlights the importance of reliable biomarkers to
route the best molecular-based therapeutic options in HCC.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Several studies recently reported molecular alterations and acti-
vation of oncogenic pathways (i.e., Wnt, Ras/MAPK, Akt/mTOR
signalling) in the pathogenesis of hepatocellular carcinoma
(HCC) [1]. A signiﬁcant number of molecular agents targeting
these signalling routes have been designed and are currently
under investigation [2]. HCC is a complex and heterogenous dis-
ease at the molecular level, and many attempts have been made
to provide a molecular classiﬁcation of this type of tumor [3,4]
because different pathways can be aberrantly activated in dis-
tinct subgroups of patients.
In such heterogeneity of pathway-activation, a personalized
therapeutic approach aiming at speciﬁc inhibition of the
observed alterations, alone or in combination, would improve
the treatment efﬁcacy of molecular targeted agents [5].
We herein report the ﬁrst case of such a personalized
approach aimed at treatment of a patient with late HCC recur-
rence after liver transplantation: the described steps could be
taken as a proof of principle for innovative perspectives of treat-
ment in patients with HCC not-eligible for conventional
therapies.Case report
A 46-year old male, with Child-Pugh B8 cirrhosis related to hep-
atitis C (HCV) and presence of an early HCC with an alpha-feto-
protein (AFP) serum level of 21 U/ml, underwent deceased-
donor liver transplantation in 1997. While waiting 7 months for
the transplantation, the patient underwent two sessions of10 vol. 52 j 771–775
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trans-arterial chemoembolization (TACE), which stabilized the
disease. There was no preoperative biopsy of the liver nodule,
which was diagnosed as HCC according to radiologic criteria
[6]. The post-transplant course was uneventful and cyclospor-
ine-based immunosuppression without steroids was initiated. A
four cm, capsulated, moderately differentiated (G2) [7,8] HCC,
with microvascular invasion (mVI) and with about ten microsat-
ellites, was found on the explanted liver. There was no necrosis in
the treated nodule and malignant cells were not found in the
thrombus, detected intraoperatively in the main portal vein.
HCV graft hepatitis occurred after 6 months and inter-
feron + ribavirin treatment was initiated and continued at various
dosages, formulations, and intervals for 5 years. Periodic ﬂares in
transaminases and HCV-RNA serum levels were managed, while
sustained viral response was never achieved. At multiple biop-A0
B0
Fig. 1. CT response to combined sorafenib + everolimus treatment. (A0 and B0) (left sid
the transplanted liver. (A1 and B1) (right side of the ﬁgure): 3 months after combined so
modiﬁed criteria [15] was observed.
772 Journal of Hepatology 201sies, Ishak scores [9] of 11–13 with mild ﬁbrosis (F2 [10]) and
mild to severe steatosis were noticed from the second post-trans-
plant year onwards, with the patient showing adequate liver
function and no signs of portal hypertension throughout the
entire follow-up.
Eleven years after transplant (October 2008) a two cm solid
nodule in the subcutaneous tissue of the lower abdomen was
detected at the level of the right anterior axillary line, on the right
side of the umbelicus. This was surgically removed and revealed
to be a G2 hepatocellular carcinoma. Less than 2 months later,
multiple and bilateral liver lesions of <1 cm in size were revealed
in a CT-scan, while the rest of the metastatic workup was nega-
tive and AFP remained at 6.2 U/ml. The presence of two sites of
peritoneal tumor spread at the subsequent laparotomy, let the
plans of combined resection and ablation of the intra-hepaticA1
B1
e of the ﬁgure): Before treatment: a multifocal, bilobar HCC recurrence is shown in
rafenib + everolimus therapy: a partial response of about 50% according to RECIST
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HCC recurrence to be abandoned. In February 2009, considering
the presence of extra-hepatic disease not amenable to intra-arte-
rial treatments, the patient was placed on sorafenib (Nexavar-
Bayer at a 400 mg bid dosage and with a grade one hand–foot
toxicity (NCI-CTCAE v3.0 [11]) and 3 months later a progression
in tumor burden was assessed, due to diffuse multinodular
intra-hepatic HCC growth (Fig. 1A0 and B0: pre-treatment). Mean-
while, the expression of surrogate markers of activation of the
principal pathways deregulated in HCC, were investigated in
the resected specimen.
Mutational analysis of the CTNNB1 gene [12] (encoding b-
catenin) showed the same point mutation in exon 3 (GGA? AGA
G34R) in both primary and recurrent HCC specimens collected
11 years apart (Fig. 2). In order to conﬁrm the true recurrent nat-
ure of HCC, analysis of microsatellite loci through PCR reactions
was performed in nine sets of polymorphic microsatellite
sequences (D18S478, D18S1102, D18S474, D18S64, D18S68,
D18S61, D18S1161, D18S462, D18S70 obtained from Applied Bio-
systems and analysed by Peak Scanner™ software) spanning
the entire long arm of chromosome 18. Six out of nine microsat-
ellite loci were successfully ampliﬁed from DNA extracted from
the cirrhotic tissue surrounding the primary tumor and from
the recurrent HCC. In six out of six (100%) there was an exactFig. 2. Identical mutation in exon 3 (GGA? AGA G34R) of the b-catenin gene,
detected in RT-PCR on both primary (upper panel) and recurrent HCC (lower
panel) specimens taken 11 years apart, demonstrated the recurring nature of
the tumor. This was also conﬁrmed after DNA microsatellite analysis (see text).
Fig. 3. Immunostaining testing b-catenin (Wnt pathway), pERK (Ras/MAPK pathway)
cytoplasm and nucleus of most tumor cells. (B) pERK (40) is positive only in the sin
cytoplasm of most tumoral cells and in the endothelium. Based on the results of these
sorafenib and everolimus was taken.
Journal of Hepatology 201match of allelic sizing, conﬁrming that all of the evaluated spec-
imen belonged to the same individual. Conversely, there was a
clear mismatch between the non-tumoral tissue in the native
liver and the donor’s graft.
In addition both primary and recurrent tumors were strongly
positive for cytoplasmic and nuclear b-catenin immunostaining
(Transduction Laboratories) demonstrating the activation of
Wnt signalling (Fig. 3A).
Phosphorylation of ERK and S6 effectors, as indicators of Ras/
MAPK and Akt/mTOR signalling activation, were then assessed at
immunohistochemistry as previously reported [13,14]. ERK/pERK
(Antibody phosphoThr202/Tyr204, Cell Signaling Technology
Inc.) was not expressed in tumoral cells and positive only in
the endothelial cells (Fig. 3B), while S6/pS6 (Antibody #2217, Cell
Signaling Technology Inc.) was highly expressed and phosphory-
lated in both clusters of tumoral cells and in the endothelium
(Fig. 3C).
Since phosphorylation of S6 represents the downstream target
of the mTOR pathway, we decided to add an mTOR inhibitor
(Certican-Novartis: 1.5 mg bid, orally) to the patient’s therapy
after 3 months of sorafenib alone, counting also on everolimus’
immunosuppressive properties after transplantation. Following
that, chronic cyclosporine immunosuppression was withdrawn.
Three months after the sorafenib + everolimus combination
was started, a response of about 50% according to RECIST criteria
modiﬁcations [15] was observed in the CT-scan, as for a total
diameter of contrast-enhanced areas in tumor nodules changing
from 96.3 cm (in 84 nodules) to 48.6 cm (in 45 nodules)
(Fig. 1A1 and B1: post-treatment). At present, 8 months after
the initiation of the combination therapy, the patient is alive
and well with an apparent further reduction of tumor vital areas,
although a recent grade II haemorrhage of the gastric mucosa led
to temporary withdrawal of the multikinase-mTOR inhibitor
combination.Discussion
This is the ﬁrst description of an individualized molecular
approach aimed to identify aberrant activation of the principal
signalling routes deregulated in HCC in a patient with recurrent
tumor in the particular scenario of post-transplantation manage-
ment. The panel of staining assembled for this case represents an
accepted methodological approach in investigating the b-catenin/and pS6 (Akt/mTOR pathway). (A) b-Catenin (40) is strongly positive in both the
usoids (arrows) while tumor cells are negative. (C) pS6 (20) is positive in the
panels of immunostaining, a decision to treat the patient with a combination of
0 vol. 52 j 771–775 773
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Wnt, Ras/MAPK, and Akt/mTOR signalling pathways and a com-
promise of feasibility and accessibility in term of cost in most
of the pathology services operating in general hospitals.
Beta-catenin activation represents the downstream event of
Wnt signalling, one of the principal proliferation pathways. The
mutation of b-catenin is a frequent event in HCC [16]: it induces
b-catenin stabilization and translocation to the nucleus, where it
interacts with T-cell-speciﬁc transcription factor (TCF/LEF). This
leads to transcriptional activation of multiple genes including c-
myc, c-met, cyclin D1, and others. Although Wnt signalling is
aberrantly activated in a high fraction of HCCs, none of the bio-
logical agents targeting this pathway have proven to be effective
[17], and therefore no clinical application can be recommended.
In the presented case, a mutation in exon 3 of the CTNNB1
gene, and the b-catenin positive nuclear immunostaining indi-
cated aberrant activation of the Wnt pathway: a rather frequent
condition indicating the need of DNA microsatellite analysis in
both primary and recurrent tumors to conﬁrm the same point
mutation and therefore the diagnosis of a true recurrent HCC, also
considering that seeding of cancer cells was excluded by the
absence of any percutaneous tumor biopsy preceding
transplantation.
Recurrence of HCC more than 10 years after transplantation is
very rare [18] and the pathogenesis of such an event should be
investigated in large sample sizes, also in light of the possible role
of liver stem cells involvement, due to their capacity of long-last-
ing latency. Their immunophenotypical characterization as well
as their role in HCC development warrant further studies [19].
Activation of Ras/MAPK signalling represents a common hall-
mark in cancer [20]. It is a dominant network, promoting cell pro-
liferation and survival. Binding of multiple growth factors (e.g.
EGF and IGF) to their receptors (e.g. EGFR, IGF1R) induces activa-
tion of Ras and downstream effectors (B-Raf, MAPK). Phosphory-
lation of ERK induces activation of transcription factors (e.g. c-
Jun) which, in turn promote transcription of genes involved in
cell growth and proliferation.
Sorafenib is a multikinase inhibitor targeting B-Raf activity,
amongst others. The presence of pERK in tumoral cells, and its
role as predictive marker of response to sorafenib, has recently
been reported [21]. We tested for ERK/pERK, by means of immu-
nohistochemistry. This revealed that it was weakly expressed and
non-phosphorylated in tumoral cells, while pERK was positively
expressed in peritumoral endothelial cells; a condition that has
not been elucidated yet.
mTOR signalling is aberrantly activated in about 50% of
human HCCs and different molecular alterations underline mTOR
deregulation (EGFR up-regulation, RAS/MAPK, PI3K/AKT up-regu-
lation, PTEN down-regulation, RICTOR copy number gain) [13]. It
is known that PTEN down-regulation leads to steatosis, inﬂam-
mation, and cancer at later stages [22] and in line with these
observations our patient had recurrent HCV infection, was over-
weight with a body mass index of 31, and a biopsy showed mod-
erate to severe steatosis and ﬁbrosis at the time of HCC
recurrence.
Phosphorylation of S6 represents the downstream effector of
mTOR signalling activation and is considered to be a molecular
surrogate of mTOR activation; therefore, predictive of tumor
response to mTOR inhibitors. Due to the importance of mTOR sig-
nalling in HCC, speciﬁc inhibitors targeting this pathway have
been developed and tested in experimental models. Among them,
the effectiveness of everolimus (a rapamycin analogue) has774 Journal of Hepatology 201recently proven to decrease tumor growth and expand survival
in xenograft models of HCC [13,23]. This was the rationale for
testing S6, results which revealed that it is expressed and
phosphorylated.
As we did not observe any beneﬁts during sorafenib mono-
therapy and since positivity for pS6 was demonstrated in the
tumor specimen, we decided to add everolimus to the patient’s
treatment. The combination of sorafenib and everolimus inhibits
multiple targets (e.g. VEGFR, Ras/MAPK and mTOR), has proven to
be effective in different studies [14,24], and ﬁnds its rationale in a
signalling feedback loop stemming from the use of mTOR inhib-
itors which leads to the activation of MAPK pathway that, there-
fore, may be silenced by the maintenance of sorafenib [25].
Moreover, mTOR inhibitors themselves have shown anti-tumoral
effects in combination with other therapies in experimental mod-
els of HCC, such as TACE, doxorubicin and bevacizumab [26,27].
In the present case the sorafenib-everolimus combination led
to signiﬁcant tumor response, although a serious adverse event
was registered with consequent temporary drug withdrawal. A
more precise determination of the potential toxicity of combining
molecular targeted drugs will be among the endpoints of ongoing
trials testing such treatment perspectives, especially for long-
lasting prescriptions.
In conclusion, as shown in large studies elucidating the geno-
mic complexity of HCC, the activation of different signalling path-
ways is not uniform in all HCC patients [1], and therefore it would
be desirable to know a priori which pathway is activated in every
patient. According to this, we investigated before treatment the
expression of surrogate indicators of signalling activation by
immunohistochemistry and in fact the described case represents
the ﬁrst example of a personalized approach to molecular tar-
geted therapy for an advanced recurrent HCC in the clinical trans-
plant setting.
The success of the combination of sorafenib and the mTOR
inhibitor everolimus, although limited to a single case, is a proof
of principle supporting the pivotal role of mTOR signalling in HCC
[13] and supports the value of such a treatment perspective in
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